+Search query
-Structure paper
Title | Design of proteasome inhibitors with oral efficacy in vivo against and selectivity over the human proteasome. |
---|---|
Journal, issue, pages | Proc Natl Acad Sci U S A, Vol. 118, Issue 39, Year 2021 |
Publish date | Sep 28, 2021 |
![]() | Stanley C Xie / Riley D Metcalfe / Hirotake Mizutani / Tanya Puhalovich / Eric Hanssen / Craig J Morton / Yawei Du / Con Dogovski / Shih-Chung Huang / Jeffrey Ciavarri / Paul Hales / Robert J Griffin / Lawrence H Cohen / Bei-Ching Chuang / Sergio Wittlin / Ioanna Deni / Tomas Yeo / Kurt E Ward / Daniel C Barry / Boyin Liu / David L Gillett / Benigno F Crespo-Fernandez / Sabine Ottilie / Nimisha Mittal / Alisje Churchyard / Daniel Ferguson / Anna Caroline C Aguiar / Rafael V C Guido / Jake Baum / Kirsten K Hanson / Elizabeth A Winzeler / Francisco-Javier Gamo / David A Fidock / Delphine Baud / Michael W Parker / Stephen Brand / Lawrence R Dick / Michael D W Griffin / Alexandra E Gould / Leann Tilley / ![]() ![]() ![]() ![]() ![]() ![]() |
PubMed Abstract | The proteasome is a potential antimalarial drug target. We have identified a series of amino-amide boronates that are potent and specific inhibitors of the 20S proteasome (20S) β5 active site and ...The proteasome is a potential antimalarial drug target. We have identified a series of amino-amide boronates that are potent and specific inhibitors of the 20S proteasome (20S) β5 active site and that exhibit fast-acting antimalarial activity. They selectively inhibit the growth of compared with a human cell line and exhibit high potency against field isolates of and They have a low propensity for development of resistance and possess liver stage and transmission-blocking activity. Exemplar compounds, MPI-5 and MPI-13, show potent activity against infections in a SCID mouse model with an oral dosing regimen that is well tolerated. We show that MPI-5 binds more strongly to 20S than to human constitutive 20S (20Sc). Comparison of the cryo-electron microscopy (EM) structures of 20S and 20Sc in complex with MPI-5 and 20S in complex with the clinically used anti-cancer agent, bortezomib, reveal differences in binding modes that help to explain the selectivity. Together, this work provides insights into the 20S proteasome in , underpinning the design of potent and selective antimalarial proteasome inhibitors. |
![]() | ![]() ![]() ![]() |
Methods | EM (single particle) |
Resolution | 3.1 - 3.4 Å |
Structure data | EMDB-23574, PDB-7lxt: EMDB-23575, PDB-7lxu: EMDB-23576, PDB-7lxv: |
Chemicals | ![]() ChemComp-BO2: ![]() ChemComp-YHD: |
Source |
|
![]() | HYDROLASE / proteasome / plasmodium falciparum / malaria / drug / bortezomib |